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Abstract: Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%–60% of 
postmenopausal women who are suffering in silence from this condition. Hormonal changes, 
especially hypoestrogenism inherent in menopause, are characterized by a variety of symptoms. 
More than half of menopausal women are concerned about the symptoms of VVA, such as 
dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia, and 
spotting during intercourse. All these manifestations significantly reduce the quality of life and 
cause discomfort in the sexual sphere. However, according to research, only 25% of patients with 
the symptoms of VVA receive adequate therapy. This is probably due to the lack of coverage 
of this problem in the society and the insufficiently active position of specialists in the field of 
women’s health regarding the detection of symptoms of VVA. Many patients are embarrassed 
to discuss intimate complaints with a specialist, which makes it difficult to verify the diagnosis 
in 75% of cases, and some patients regard the symptoms of VVA as manifestations of the 
natural aging process and do not seek help. Modern medicine has in the arsenal various options 
for treating this pathological condition, including systemic and topical hormone replacement 
therapy, the use of selective estrogen receptor modulators, vaginal dehydroepiandrosterone, use 
of lubricants and moisturizers, as well as non-drug therapies. Timely diagnosis and adequately 
selected therapy for the main symptoms of VVA lead to restoration and maintenance of the 
vaginal function and vaginal health.
Keywords: vulvovaginal atrophy, vaginal dryness, dyspareunia, menopause, hormonal replacement 
therapy, local estrogen, selective estrogen receptor modulator, vaginal dehydroepiandrosterone
Introduction
Menopause is a phenomenon that inevitably occurs in the life of every woman. The 
mean age of menopause in European countries is between 46.7 and 50.1 years.1 This 
period is characterized by the loss of hormonal function of the ovaries. With increased 
life expectancy, the impact of vulvovaginal atrophy (VVA) on the quality of life, sexual 
function, and pelvic floor health is becoming more evident in the present practice of 
medicine. Clinical manifestations of the menopausal syndrome are diverse and deter-
mined by the duration of hypoestrogenism. Genitourinary syndrome of menopause is 
one of the most frequent complaints referred by postmenopausal women. Genitourinary 
syndrome of menopause is a recent terminology that describes an assortment of exam 
findings and bothersome symptoms related to estrogen deficiency that involves changes 
in the labia, introitus, clitoris, vagina, urethra, and bladder. VVA is just a component 
of this general condition. Characterized by a chronic progressive course, VVA sig-
nificantly impairs the quality of life and sexual health of women.
Women affected by this condition may present a variety of symptoms includ-
ing vaginal and vulvar pain and irritation. Vaginal dryness due to hypoestrogenism 
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can be accompanied by itching, burning, discharge, and 
dyspareunia.2 Some women also develop fear of pelvic 
examinations. Frequency of occurrence of VVA, severity 
of pathological changes, and clinical course of the disease 
depend on the duration of postmenopause. In the first years 
after the termination of menstruation, involuntary changes 
in the vaginal mucosa are not very pronounced, and only 
4% of women have clinical manifestations of this condition 
according to the literature. As the estrogen deficiency grows, 
dystrophic and atrophic changes develop in the vaginal 
mucosa, vulva, and other structures of the urogenital tract. 
Thus, in 7–10 years after the termination of menstruation, 
atrophic changes are observed in almost 50% of women, 
and with time, their frequency increases to 73%–75% (while 
about 70% of women with symptoms of vaginal atrophy do 
not turn to doctors, considering it a natural condition).
Recently, the European Vulvovaginal Epidemiological 
Survey was carried out, in which .2,000 postmenopausal 
women were examined. Symptoms of VVA were detected 
in 90% of women. According to the results of the survey, 
the quality of life in this group of women was significantly 
lower in comparison to that of women of postmenopausal 
age without symptoms of VVA.3
The mucus membrane of the lower sections of the uro-
genital tract is very sensitive to the effects of estrogens. 
A sufficient level of these hormones ensures a good blood 
supply to the vaginal mucosa and the optimal level of lubrica-
tion is maintained.4 Furthermore, estrogens may also induce 
proliferation of layers of vaginal wall epithelium as well as 
smooth muscle fibers and collagen maintaining the rugae of 
the vagina.5 By mingling, cells of stratified squamous epithe-
lium, rich in glycogen, are a nutrient substrate for the bacteria 
of the vaginal microbiota. Vaginal microbiota is a dynamic 
variable system, represented by a variety of bacteria, the vital 
activity and balance of which provides vaginal homeostasis. 
The importance of microbiota in the formation of vaginal 
health cannot be underestimated. The dominant constituent 
of the vaginal microbiota is lactobacillus. Production of lactic 
acid, as a result of the vital activity of these bacteria, ensures 
the maintenance of the optimum low pH of the vaginal fluid, 
thus protecting from infections of the urogenital tract. The 
low pH of the vaginal fluid is also maintained by the active 
proton transport by the vaginal epithelium formed because 
of anaerobic glucose metabolism.6–9
Under hypoestrogenic conditions, the vaginal epithelium 
becomes thinner, its barrier function is lost, the vaginal fold-
ing decreases, the elasticity of the tissues decreases, and the 
secretory activity of the Bartholin glands decreases, which 
lead to traumatization of the vaginal mucosa and painful 
sensations (Figure 1).5,10,11
Figure 1 Cascade effects of the mechanism of vvA.
Abbreviation: vvA, vulvovaginal atrophy.
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In addition, under conditions of estrogen deficiency, the 
balance of the vaginal microbiota is disrupted, the pathogenic 
gram-negative fecal flora and other bacteria prevail in its 
composition, and the vagina develops a less acidic pH, that 
is, from 5.5 to 6.8.9,12 In studies by Brotman et al, a correlation 
between the nature of the vaginal microbiota, the low lacto-
bacillus content, and the development of VVA was noticed. 
The data obtained by the authors demonstrate differences in 
the vaginal microbiota of pre-, peri-, and postmenopausal 
women. In the proposed hypothesis, the predominance of 
anaerobic flora in the vaginal environment plays a role in 
the development of VVA symptoms.13
Clinical impact
Clinically, VVA is manifested by dryness in the vagina, 
dyspareunia, vaginal discharge, itching, and pain.4,14
Dyspareunia leads to a decrease in sex drive and fear of 
sexual intercourse. As the frequency of coitus diminishes, 
vaginal lubrication declines further.15
Some women may already have narrowing of the vagina 
or manifestations of vaginismus, limiting the penetration 
into the vagina.
However, in some women with mild-to-moderate sever-
ity, VVA occurs asymptomatically and verification of diag-
nosis is possible only with vaginal examination.16
The diagnosis of VVA is made difficult by the low aware-
ness of women about the pathological manifestations of the 
postmenopausal period and unwillingness/embarrassment 
to discuss the symptoms of an intimate character with the 
expert. In their study, Nappi and Kokot-Kierepa noted that 
only 4% of respondents associated their symptoms with 
the manifestations of menopause.17 Unfortunately, 75% of 
patients with the clinical manifestations of VVA do not seek 
help from specialists.5
According to Nappi et al, only 54% of menopausal women 
are willing to discuss their sexual health with a specialist and 
33% of patients even refuse to answer questions.18
The experts in the field of women’s health are faced with 
the task of early detection of VVA and the timely administra-
tion of etiopathogenetic treatment.
In terms of the survey, a detailed history of the patient 
with a suspicion of VVA should be conducted to identify 
the possible causes, including effects of irritants (lubricants, 
hygienic gels, soaps, spermicides), the use of antiestrogen 
drugs, advanced oophorectomy, or chemotherapy.
The diagnosis is confirmed by vaginal examination and 
colposcopy, wherein atrophic epithelium and thin, pale, and 
easily traumatized petechial hemorrhages can be detected.
It is necessary to carry out bacteriological studies, deter-
mine the acidity of the vaginal contents, perform cytological 
examination of the vaginal smears, and count the karyopic-
notic index.
Differential diagnosis has to be performed with the condi-
tions summarized in Table 1.
The main therapeutic goal in managing VVA is to relieve 
symptoms and restore the vaginal environment to a healthy 
premenopausal state. However, despite the high prevalence 
and negative impact on the quality of life, VVA is under-
reported by patients, undiagnosed by health care providers, 
and undertreated. Gynecologists should proactively start an 
open discussion with patients on urogenital symptoms. Treat-
ment should be started as early as VVA occurs and should be 
maintained over time. As there are many treatment options, 
therapy should be individualized.
Table 1 Differential diagnosis of vvA
Condition Main symptoms and signs
vaginal infections vaginal discharge (leukorrhea, 
xanthorrhea), pruritus, bad smell
Allergic reactions Redness, swelling, pruritus, 
occasionally blistering, and pain
Lichen planus Painful, red plaques or erosions with 
white or violaceous borders; may 
extend into vagina
Lichen sclerosis Coalescing ivory and pink plaques in 
butterfly of crinkled, wax-like tissue. 
May result in labial and clitoral hood 
agglutination
Ulcers and cracks in the  
external genitalia associated  
with systemic diseases: Behçet
There are intensely painful, punched-
out ulcers, which are often bilateral, 
with a yellow-white base and red 
borders
Ulcers and cracks in the  
external genitalia associated  
with systemic diseases: Crohn
Mixed inflammatory lesions, fissures, 
and “knife-cut” ulcers of variable 
severity. May progress into fistulae; 
most commonly, in perianal or 
rectovaginal sites. Marked painless 
vulval edema may occur
Acute vulvar ulcers or  
Lipschütz ulcers
Acute painful genital ulcerations 
of the vulva or lower vagina. 
May appear in nonsexually active 
adolescent girls or young women
Other vulvovaginal ulcers Gluten enteropathy, systemic lupus 
erythematosus, Stevens–Johnson 
syndrome, pyoderma, pemphigus 
vulgaris, pemphigoid, and so on
Tumors of the urogenital  
tract
Presented as multifocal red, white, 
or dark raised or eroded neoplasm 
lesions, or as solitary ulcer with 
raised or indurated edge
extramammary Paget disease Brick red, scaly, eczematoid plaque 
with sharply demarcated border and 
sometimes a roughened surface
Abbreviation: vvA, vulvovaginal atrophy.





Women’s perspectives on and 
options for treatment of 
genitourinary syndrome of 
menopause – VVA
Treatment of VVA depends on the severity of the symp-
toms of the disease and on the preferences and expectations 
of women.
Lubricants and moisturizers
According to the generally accepted international standards, 
the first-line recommendations for the treatment of mild and 
moderate manifestations of VVA are nonhormonal vaginal 
lubricants that should be used before intercourse and vaginal 
moisturizers with a long-term effect that are used regularly 
(several times a week); in such cases, regular sexual activity 
is of importance.
This treatment option is also recommended for women 
for whom the use of vaginal estrogen preparations is 
unacceptable.19
Lubricants provide a short-term relief from vaginal 
dryness and discomfort during sexual intercourse.
They may be water, silicone, or oil based and are 
applied to the vulva, vagina, or penis before sexual activity. 
Lubricants with a water base have fewer side effects, which 
is an advantage compared to lubricants based on silicone.19 
The literature contains sparse data on the safety of lubricants 
based on oils, the effect on motility of spermatozoa, and the 
properties of condoms. There is also evidence of an increased 
risk of developing bacterial vaginosis and vaginal candidiasis 
with the use of these medications.20–22
Vaginal moisturizers have a long-lasting effect in reliev-
ing the symptoms of VVA, enhancing moisturizing of the 
vaginal mucosa, and reducing the pH. These drugs are pre-
scribed on a regular basis: daily or every 2–3 days, depending 
on the extent of the symptoms.19 According to Chen et al, 
the use of hyaluronic acid vaginal gel every 3 days causes 
improvement in symptoms of vaginal dryness, comparable 
with the effect of topical estrogen therapy.23
When choosing lubricants and moisturizers, it is impor-
tant that the product is similar to vaginal secretion in terms 
of osmolality, pH, and composition.19
Vaginal lubricants and moisturizers can be used as needed 
in combination with other VVA treatments.
Hormone therapy (local and systemic)
Considering the cause (hypoestrogenism), and the pathogen-
esis of the development of VVA, the most logical choice for 
the treatment of this condition would be estrogen therapy. 
However, for most physicians and scientific societies, it is 
a second-line treatment after moisturizers and lubricants. 
Replenishment of estrogen deficiency can be carried out with 
hormonal preparations with systemic and local action, as well 
as with preparations of plant origin. According to the latest 
clinical guidelines for the management of patients with VVA, 
systemic or topical application of pharmacological estrogen 
preparations sufficiently and quickly improves the index of 
maturation and thickness of the vaginal mucosa, reduces the 
pH of the vagina, increases vaginal maturation index, and 
eliminates the symptoms of VVA.5,8,10,24,25
Systemic hormone replacement therapy (HRT) includes 
all preparations containing estradiol, estradiol valerate, or 
conjugated estrogens.
Systemic HRT is prescribed in the case of a combination 
of symptoms of urogenital atrophy with other symptoms 
of climacteric syndrome, as well as for the prevention and 
treatment of late-onset manifestations of the syndrome and 
its complications.
The local HRT includes preparations containing 
estradiol, as well as estriol. Local estrogen therapy is pre-
ferred in the presence of isolated urogenital disorders; the 
patients should be informed that the effect is achieved after 
1–3 months of local estrogen therapy, and that they should 
be able to choose the drug that they consider most appropri-
ate for them.8,24
Studies have shown that systemic HRT eliminates the 
symptoms of vaginal atrophy in 75% of cases, while local 
therapy does so in 80%–90% of cases.12
Estrogen therapy is prescribed after a clinical examina-
tion, identifying the risk factors for possible complications, 
and explaining the information to the patient. Low doses of 
estrogens are preferred for use, since the use of high doses 
of estrogen in menopausal age is associated with a high risk 
of hyperproliferative endometrial and adenocarcinoma.15
Absorption of low-dose vaginal estrogen preparations 
into the systemic blood stream is minimal and serum estradiol 
level does not exceed the physiological value for the post-
menopausal period.26 Such a route of administration of drugs 
allows to avoid hepatic metabolism, which minimizes the 
risk of side effects inherent in systemic estrogen therapy and 
excludes the effects on the endometrium and breast tissue, 
and thus, there is no need to prescribe progesterone prepa-
rations for the prevention of endometrial hyperplasia and 
adenocarcinoma. Local estrogen therapy allows to quickly 
eliminate the symptoms of VVA, but it does not alleviate the 
vasomotor symptoms and reduce the risk of osteoporosis.
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According to the North American menopausal community, 
when taking low-dose vaginal estrogen preparations, the fol-
lowing ones occur: a decrease in the rugae of the vagina, an 
increase in the number of lactobacilli, and an improvement 
in the state of the vaginal epithelium and the epithelium of 
the urethra.4
Pharmaceutical estrogen-containing preparations for 
topical use are available in the form of a cream, tablets, and 
a vaginal estrogen-releasing ring which may contain estriol, 
conjugated equine estrogens, estradiol, or estrone (Table 2).
According to the 2006 Cochrane review, all forms of 
drug administration are equally effective in providing relief 
from vaginal dryness, dyspareunia, and pruritus. As well, 
there are no significant differences in the thickness of the 
endometrium, the incidence of endometrial hyperplasia, and 
side effects.25,27
However, an insignificant risk of vaginal bleeding has 
been described in all studies in which various methods of 
topical estrogen therapy have been used.
The choice of the form of administration of the drug is 
determined by the patient’s preference.
The most commonly used form of local estrogen therapy 
is vaginal creams based on conjugated equine estrogens 
and 17b estradiol; they provide a good moisturizing effect. 
However, the amount of cream administered can vary, 
exceeding the recommended daily dosage, which is particu-
larly undesirable for patients at high risk. According to data 
of Kingsberg et al, several women experience discomfort 
when using vaginal cream, finding it messy.28
If more controlled dosing of estrogen is required, the 
drug of choice may be vaginal tablets containing 10 mg of 
estradiol.
During the first 2 weeks of use, the daily use of the 
above-mentioned drug groups is recommended, followed 
by a transition to maintenance therapy with a dose of two to 
three times a week.15
Sustained-release estradiol vaginal rings are preferred for 
women for whom daily use of drugs is unacceptable. Vaginal 
rings are inserted for up to 90 days and can be independently 
installed and removed by the patient. However, depending on 
the daily dose of estrogens, such systems can facilitate not 
only urogenital symptoms, but also vasomotor manifestations 
of the climacteric syndrome.26
The use of vaginal rings is not recommended in women 
with prolapse of the genitals. It is also necessary to warn a 
woman about the possible expulsion of the vaginal ring.
In the studies of Constantine et al,29 Simon et al,30 and 
Pickar et al,31 a good result regarding the rapid relief from 
the symptoms of VVA was noted when using gel capsules 
with estradiol, released at a dose of 4, 10, and 25 µg. At the 
same time, the absorption of the drug into the systemic 
circulation and the maximum concentration of estradiol in 
the serum were significantly lower in comparison with the 
use of vaginal tablets.29–31 The authors noted relief from the 
main symptoms of VVA for a few weeks after the use of 
vaginal capsules, but in most cases, it took up to 12 weeks 
of therapy to completely relieve the symptoms. However, 
clinical observations of the use of this group of low-dose 
estrogens are limited to 1 year.
Several clinical studies have also noted improvements 
in urinary symptoms, such as urgency, frequency, nocturia, 
and stress and urgency urinary incontinence.25
Very interesting are the data published by Santen, where 
various variants of local estrogen therapy (low-, intermediate-, 





Initial dosage Maintenance dosage
vaginal cream estradiol-17b estrace 0.01% 0.5–1 g daily for the 
first 2 weeks




Premarin 0.625 mg/g 0.5–1 g daily for the 
first 2 weeks
0.5–1 g one to three times 
weekly
vaginal tablets estradiol 
hemihydrate
vagifem, Yuvafem 10 µg once daily for 
the first 2 weeks
One or two times per week
vaginal capsules estradiol-17b 
softgel capsules
TX-004HR 4/10/25 µg daily for  
2 weeks
One or two times per week
vaginal ring estradiol-17b estring 2 mg (releases  
7.5 µg daily)
Insert for 90 days
estradiol acetate Femring 12.4/24.8 mg (releases 
0.05/0.1 µg daily)





60 mg daily 60 mg daily
Abbreviation: SeRM, selective estrogen receptor modulator.





and high-dose) and their adsorption into the systemic circu-
lation are considered. The author compared the peak con-
centrations of estrogens and the “chronic concentration” of 
estrogens in the blood plasma as a result of adsorption with 
prolonged use. According to data analysis of .30 studies, 
the use of low-dose vaginal estrogens (7.5 µg silastic vaginal 
ring and a 10 µg estradiol tablet [eg, VagifemR]) showed 
adsorption to the systemic circulation, but during long-term 
administration the estradiol levels were ,20 pg/mL.32 How-
ever, according to several authors, against the background of 
long-term use of low-dose local estrogens, systemic effects 
on bone resorption and serum lipid were observed.33,34
The intermediate- and high (systemic)-dose regi-
mens include 25 µg of higher estradiol preparations. The 
intermediate- and high-dose vaginal estradiol preparations 
are well absorbed, and they maintain the concentration 
of estrogens in the plasma corresponding to the period of 
premenopause.32
When administering local and systemic estrogen prepara-
tions, it is necessary to remember the side effects of drugs 
associated with systemic adsorption and carefully assess the 
risks of complications. Excess estrogen levels in postmeno-
pausal women are associated with an increased risk of heart 
disease, breast cancer, thromboembolic complications, and 
cerebrovascular diseases.35 Preference should be given to 
low-dose local estrogens, especially if the therapy is pre-
scribed to aged patients.
However, in spite of the vast amount of positive data 
showing improvement of vaginal health and sexual function 
with estrogens and moisturizers, recent data by Mitchell 
et al generate controversy as they have shown no benefits 
on comparing both with placebo.36 Though the authors note 
that the study was conducted in a homogeneous population of 
patients, in contrast to other studies that limit the inclusion of 
a woman with a high vaginal pH in the study, all postmeno-
pausal women with symptoms of moderate or severe VVA 
were included in this study. Evaluation of the effectiveness 
of therapy was limited to a 12-week period.
Selective estrogen receptor 
modulators
Selective estrogen receptor modulators (SERMs) are another 
option for VVA treatment among women in whom estrogen 
preparations are contraindicated.
SERMs are structurally different and interact with intra-
cellular estrogen receptors in the target organs as agonists 
or antagonists of estrogens.
In 2013, the drug of this group (ospemifene) was 
approved for use by the US Food and Drug Administration 
(FDA) and is now successfully used in USA and Europe. 
The literature has already accumulated sufficient reports on 
the use of oral ospemifene.
Ospemifene has relatively weak estrogenic and antiestro-
genic effects in classical hormonal tests, has an anti-osteoporosis 
effect, and reduces the level of total cholesterol.
A comparable effect with vaginal estrogens has been 
noted regarding alleviating the symptoms of vaginal atrophy 
and dyspareunia, improving the vaginal epithelium and pH 
of the vagina.37 The results of the studies with ospemifene 
show significant increase in the percentage of surface cells 
of the vaginal epithelium and a decrease in the percentage 
of parabasal cells and a decrease in vaginal pH.38
Constantine et al, in their double-blind, placebo-controlled 
study, found the efficacy and safety within 1 year of using 
ospemifene. No cases of endometrial cancer were reported 
and only ,1% of patients had endometrial hyperplasia. The 
incidence of thromboembolism associated with ospemifene in 
the pivotal studies was comparable to placebo; however, as a 
SERM, the class effect regarding the increased risk of venous 
thrombosis should be considered and this drug should be avoided 
in patients with an increased risk of venous thrombosis.39
Lasofoxifene is new third-generation SERM that binds 
to both estrogen receptor types and is currently not approved 
for use by the FDA.40 Lasofoxifene has a pronounced positive 
effect on the state of the vaginal epithelium and pH and pro-
vides relief from the main symptoms of VVA in comparison 
to taking placebo.38
A number of studies have shown the high efficacy of 
lasofoxifene in improving bone mineral density, as well as 
reducing the risk of coronary heart disease and stroke and 
alleviating the symptoms of VVA.41–44
A tissue-specific estrogen complex is now being devel-
oped, including a combination of SERM (bazedoxifene) with 
conjugated estrogens. In the literature, there is evidence of 
the drug causing significant relief from the symptoms of 
genitourinary syndrome without the development of endo-
metrial hyperplasia.45,46
The effect of tamoxifen in the vaginal epithelium is not 
well established; however, most of the data demonstrated 
that tamoxifen exerts antiestrogenic effect on the vaginal 
epithelium. Raloxifene slightly increased the percentage 
of vaginal superficial cells and decreased the percentage 
of parabasal cells; however, raloxifene did not improve the 
symptom of dyspareunia.47
Vaginal dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) is a steroid prohormone 
in the biosynthetic pathway of testosterone and estradiol. 
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The vaginal metabolism of DHEA into estrogens/testosterone 
leads to the activation of estrogen and androgen receptors in 
the three layers of the vaginal wall, including the fibers of the 
basal membrane collagen and the muscle wall, but the absence 
of aromatase in the normal endometrium does not lead to its 
stimulation.48 The levels of estradiol and testosterone in the 
serum may have minimal increases, without clinical signifi-
cance presumably because of local inactivation. There is a 
slight increase in the serum concentration of DHEA sulfate.
In a new prospective, randomized, double-blind clinical 
trial, Labrie et al confirmed the local beneficial effect of 
intravaginal DHEA (prasterone) on the symptoms of mild/
severe dyspareunia, the most frequent manifestation of geni-
tourinary syndrome in postmenopausal women.49
For the daily vaginal use of DHEA, Intrarosa® (prasterone) 
(6.5 mg) was recently approved by the FDA for use in the 
treatment of dyspareunia.
Laser therapies
Recently introduced in the treatment of VVA, laser vaginal 
therapy has demonstrated effectiveness as well as high satis-
faction among patients and health care providers. Data on the 
procedure were first published in 2014 and use of fractional 
microablative carbon dioxide laser therapy for genitourinary 
surgery was approved by the FDA.
Laser therapy improves the vascularization of the vaginal 
mucosa, stimulates the synthesis of new collagen and matrix 
basic substance in the connective tissue, thickens the vaginal 
epithelium with the formation of new papillae, replenishes 
glycogen in the vaginal epithelium, allows restoring the bal-
ance of the mucosa and therefore improves the symptoms of 
atrophy caused by a lack of estrogen.50–52
Salvatore et al also noted a significant improvement in 
the quality of life and sexual activity when laser therapy was 
used in women with VVA.51
In the study of Salvatore et al, 85% of women who were 
previously not sexually active due to genitourinary syndrome 
of menopause symptoms regained a normal sexual life at 
12 weeks following therapy.53 The positive effect in the 
treatment of women with VVA can be achieved by combin-
ing hormonal and non-hormonal methods of treatment. It is 
important not to forget about the positive effect of sexual 
intercourse on the improvement of vaginal health. For the 
women who do not have regular sexual intercourse or have 
vaginal narrowing, the phenomenon of vaginismus, gradual 
careful stretching of the vagina with special dilators using 
lubricants is recommended. It can play an important role in 
restoring and maintaining the vaginal function. Then, the 
resumption of regular sexual activity will help to maintain 
vaginal health. Many women with these disorders benefit from 
the exercises that strengthen the muscles of the pelvic floor. 
In those patients, the use of vaginal estrogens before and after 
the expansion of the vagina and/or therapy to strengthen the 
pelvic muscles may be useful.
Conclusion
VVA complicates the course of postmenopausal period in 
more than half of the women. Manifestations of VVA bring 
discomfort in the daily life of a woman, worsening the quality 
of life and vaginal health. Timely active detection of this 
pathological condition and providing adequately selected 
therapy can prevent the progress of the disease and signifi-
cantly improve the quality of life and sexuality of women.
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